BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:39 PM
Jul 17, 2009
 |  BC Extra  |  Clinical News

ACT-293987 meets Phase IIa endpoint

Actelion Ltd. (SIX:ATLN) said ACT-293987 met the primary endpoint of significantly improving pulmonary vascular resistance from baseline in a European...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >